LCTX - AMEX
Lineage Cell Therapeutics, Inc.
$1.21
-0.83%Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-related macular degeneration; OPC1, an oligodendrocyte progenitor cell therapy that is in Phase I/IIa multicenter clinical trial for the treatment of acute spinal cord injuries; and VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells, which is in Phase I clinical trial to treat non-small cell lung cancer. It also offers Renevia, a facial aesthetics product. In addition, the company engages in the research and development of therapeutic products for retinal diseases, neurological diseases, and disorders and oncology. Lineage Cell Therapeutics, Inc. has a collaboration with Orbit Biomedical, Ltd. The company was formerly known as BioTime, Inc. and changed its name to Lineage Cell Therapeutics, Inc. in August 2019. Lineage Cell Therapeutics, Inc. was incorporated in 1990 and is headquartered in Carlsbad, California.
At a Glance
Live SnapshotLineage Cell Therapeutics, Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Net losses indicate the company is burning cash. Sustainability depends on path to profitability.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Lineage Cell Therapeutics, Inc. Income Statement
LCTX • AMEX
| Lineage Cell Therapeutics, Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
14.6M | 9.5M | 8.9M | 14.7M | 3.9M | 773K | 1.5M | 1.4M | 1.8M | 2.3M | 2.5M | 1.9M | 2.9M | 1.7M | 4.4M | 3.7M | 1.9M | 1.5M | 1M | 1.2M | |
GROSS PROFIT | ||||||||||||||||||||
(845K) | (334K) | (671K) | (728K) | (1.4M) | (385K) | (412K) | (302K) | (168K) | (358K) | (1.1M) | (837.1K) | (792.7K) | (434.3K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
13.7M | 9.2M | 8.3M | 14M | 2.5M | 388K | 1.1M | 1.1M | 1.6M | 1.9M | 1.4M | 1.1M | 2.1M | 1.3M | 4.4M | 3.7M | 1.9M | 1.5M | 1M | 1.2M | |
OPERATING INCOME | ||||||||||||||||||||
(35.5M) | (30.6M) | (33M) | (36.5M) | (51.7M) | (26.8M) | (39.9M) | (42.1M) | (42.3M) | (60.9M) | (67.2M) | (51.8M) | (40.6M) | (26.3M) | (23M) | (13.5M) | (5.4M) | (4.3M) | (2.3M) | (2.9M) | |
(18.5M) | (18.2M) | (17.3M) | (22.5M) | (18.2M) | (15.6M) | (24M) | (24.7M) | (19.9M) | (28.4M) | (29.1M) | (17.6M) | (15.6M) | (10.4M) | (9.3M) | (5.6M) | (2.5M) | (2.6M) | (1.3M) | (1.5M) | |
(17.7M) | (12.5M) | (15.7M) | (14M) | (33.9M) | (12.3M) | (17.9M) | (21M) | (24M) | (36.1M) | (42.6M) | (37.5M) | (26.6M) | (18.1M) | (13.7M) | (7.9M) | (3M) | (1.7M) | (967.9K) | (1.4M) | |
-21.8M | -21.5M | -24.7M | -22.5M | -49.2M | -26.4M | -38.9M | -41.8M | -38.9M | -59M | -65.8M | -50.7M | -56M | -25M | -18.7M | -9.9M | -3.5M | -2.8M | -1.2M | -1.8M | |
PRE-TAX INCOME | ||||||||||||||||||||
(0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (10.9M) | (692K) | (747K) | (340K) | (91K) | (26.1M) | (305.2K) | (0.0) | (124.3K) | (1.7M) | (965.8K) | (0.0) | (157.1K) | |
1.7M | 1.7M | 1.6M | 829K | 2K | 1M | 1.7M | 711K | -692K | -747K | -340K | -89K | -578.0 | 19.4K | 29.7K | -124.3K | -1.7M | -965.8K | 0.0 | -157.1K | |
-699K | (0.0) | (0.0) | (0.0) | -445K | -1.1M | -2M | -1.3M | (1.4M) | -403K | -160K | -374.7K | -209.2K | -317.7K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-46.9M | 2.9M | 1.5M | -3.3M | 5.9M | 4.5M | 19.6M | -5.3M | 15.6M | 77.6M | 3.2M | -472.1K | -203.8K | -305.2K | 212.8K | -1.3M | -1.6M | -958.3K | -215.9K | -112.8K | |
-68.6M | -18.6M | -23.3M | -25.8M | -43.3M | -21.9M | -19.2M | -47.1M | -23.3M | 18.6M | -62.7M | -51.2M | -56.2M | -25.3M | -18.5M | -12.1M | -3.5M | -2.8M | -1.2M | -1.7M | |
NET INCOME | ||||||||||||||||||||
-5.1M | (0.0) | -1.8M | (541K) | (0.0) | -1.2M | -7.4M | -346K | (0.0) | (0.0) | -4.5M | -7.4M | -3.3M | (0.0) | -2.4M | (3.4M) | -60.2K | -15K | (388.2K) | -88.7K | |
-63.5M | -18.6M | -21.5M | -26.3M | -43M | -20.6M | -11.7M | -46M | -20M | 33.6M | -47M | -36.4M | -43.9M | -21.4M | -16.5M | -11.2M | -5.1M | -3.8M | -1.4M | -1.9M |
SEC Filings
LCTX - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
10-Q 10-Q 2026 Q1 Q1 | May 12, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 12, 2026 | May 12, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
S-3 S-3 N/A | March 11, 2026 | March 11, 2026 | ||
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 28, 2025 | November 28, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 24, 2025 | November 20, 2025 | 2025 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 |
Related Guides
Continue your LCTX research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.